Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic Target

Research output: Contribution to journalReview articlepeer-review


G protein-coupled receptors (GPCRs) are successful druggable targets, making up around 35% of all FDA-Approved medications. However, a large number of receptors remain orphaned, with no known endogenous ligand, representing a challenging but untapped area to discover new therapeutic targets. Among orphan GPCRs (oGPCRs) of interest, G protein-coupled receptor 37 (GPR37) is highly expressed in the central nervous system (CNS), particularly in the spinal cord and oligodendrocytes. While its cellular signaling mechanisms and endogenous receptor ligands remain elusive, GPR37 has been implicated in several important neurological conditions, including Parkinson's disease (PD), inflammation, pain, autism, and brain tumors. GPR37 structure, signaling, emerging physiology, and pharmacology are reviewed while integrating a discussion on potential therapeutic indications and opportunities.

Original languageEnglish (US)
Pages (from-to)3318-3334
Number of pages17
JournalACS chemical neuroscience
Issue number18
StatePublished - Sep 20 2023


  • CNS disorders
  • GPR37
  • Orphan G protein-coupled receptors (oGPCRs)
  • drug discovery
  • drug targets
  • neurotherapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology


Dive into the research topics of 'Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic Target'. Together they form a unique fingerprint.

Cite this